ARTICLE | Company News
Avastin, Humira biosimilars move forward
October 6, 2015 1:29 AM UTC
Biosimliar candidates ONS-1045 from Oncobiologics Inc. (Cranbury, N.J.) and M923 from Baxalta Inc. (NYSE:BAX) and Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) each reached clinical milestones on Monday.
Oncobiologics said ONS-1045, a biosimilar of cancer antibody Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY), met the primary and secondary bioequivalence endpoints in a Phase I pharmacokinetic (PK) study. The company plans to begin a Phase III trial of ONS-1045 in 1H16. ...